Document text
Final Agenda
10:00 Opening Remarks Dr. Martin Kulldorff (ACIP Chair)
10:15 Welcome and Roll Call Dr. Mina Zadeh (ACIP Executive Secretary, CDC)
10:35 Update on Work Groups Dr. Martin Kulldorff (ACIP Chair)
11:00 COVID-19 Vaccines
Introduction Dr. Adam MacNeil (CDC/NCIRD)
COVID-19 epidemiology Dr. Adam MacNeil (CDC/NCIRD)
COVID-19 vaccine effectiveness update Dr. Adam MacNeil (CDC/NCIRD)
COVID-19 safety update Dr. Sarah Meyer (CDC/NCEZID)
COVID-19 vaccine coverage and implementation Dr. Georgina Peacock (CDC/NCIRD)
Evidence to recommendations (partial) Dr. Adam MacNeil (CDC/NCIRD)
1:00 Lunch
1:30 Agency Updates CDC, CMS, FDA, HRSA, IHS, NIH
2:00 RSV Vaccines- Maternal/Pediatric
Introduction Dr. Adam MacNeil (CDC/NCIRD)
Updates on uptake of maternal vaccine and nirsevimab Dr. Georgina Peacock (CDC/NCIRD)
Effectiveness and impact of RSV prevention products in infants
during the 2024-2025 seasonDr. Adam MacNeil (CDC/NCIRD)
Updates on safety of maternal vaccine and nirsevimab Dr. Malini DeSilva (HealthPartners),
Dr. Matthew Daley (Kaiser Permanente Colorado)
Updates and summary of the Evidence to Recommendation
Framework for clesrovimabDr. Adam MacNeil (CDC/NCIRD)
Updates on clinical considerations for clesrovimab Dr. Adam MacNeil (CDC/NCIRD)
Proposed Recommendations Dr. Adam MacNeil (CDC/NCIRD)
Updates to RSV vaccines VFC resolution Dr. Georgina Peacock (CDC/NCIRD)
4:00 Break
4:15 Public Comment
5:00 Votes
RSV Vaccines- Pediatric Dr. Adam MacNeil (CDC/NCIRD)
RSV Vaccines- VFC Dr. Georgina Peacock (CDC/NCIRD)
5:30 AdjournMEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)
Centers for Disease Control and Prevention
Atlanta, Georgia 30329
Wednesday, June 25, 2025
Final Agenda
8:00 Welcome and Roll Call Dr. Mina Zadeh (ACIP Executive Secretary, CDC)
8:15 Influenza Vaccines
Introduction Dr. Vivien Dugan (CDC/NCIRD)
Flublok in older children and adolescents: immunogenicity and safety Dr. Pedro Folegatti (Sanofi Pasteur)
Estimates of influenza burden and burden averted through vaccination Dr. Vivien Dugan (CDC/NCIRD)
Proposed recommendations for 2025-26
Presentation regarding thimerosal in vaccines
Proposed recommendations regarding thimerosal containing influenza
vaccine
10:15 Break
10:30 Chikungunya Vaccines
Introduction
EtR (partial) for use of live attenuated and virus-like particle
chikungunya
vaccines in U.S territories
Safety update on live attenuated chikungunya vaccine and use among
older persons
10:45 Anthrax Vaccine
10:50 MMRV Vaccine
Presentation on MMRV vaccine in children under under 4 years of
age
Proposed recommendations regarding MMRV in children under 4
years of age
11:20 Break
11:30 Public Comment
12:15 Break
12:30 Votes
Influenza Vaccines
Thimerosal containing influenza vaccine recommendationsDr. Vivien Dugan (CDC/NCIRD)
Lyn Redwood, RN, MSN
Dr. Martin Kulldorff (ACIP Chair)
Dr. Lyle Petersen (CDC/NCEZID)
Dr. Lyle Petersen (CDC/NCEZID)
Dr. Lyle Petersen (CDC/NCEZID)
Dr. Brendan Jackson (CDC/NCEZID)
Dr.
Martin Kulldorff (ACIP Chair)
Dr. Martin K
ulldorff (ACIP Chair)
Dr. Vivien Dugan
Dr. Martin Kulldorff (ACIP Chair)
1:00 Adjourn
Acronyms
CDC Centers for Disease Control and Prevention
CMS Centers for Medicare & Medicaid Services
COVID-19 Coronavirus disease 2019
EtR Evidence to Recommendations Framework
FDA Food and Drug Administration
HRSA Health Resources and Services Administration
IHS Indian Health Service
MMRV Measles, Mumps, Rubella, Varicella Vaccine
NCIRD National Center for Immunization & Respiratory Diseases
NCEZID National Center for Emerging and Zoonotic Diseases
NIH National Institutes of Health
RSV Respiratory Syncytial Virus
VFC Vaccines for ChildrenThursday, June 26, 2025